Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alan S. Cross is active.

Publication


Featured researches published by Alan S. Cross.


Archive | 1993

Local and Disseminated Diseases Caused by Pseudomonas aeruginosa

Andrew W. Artenstein; Alan S. Cross

Pseudomonas aeruginosa is an organism of relatively low virulence that rarely affects those with intact host defenses. In the immunocompromised host, however, it is capable of using a wide array of potential virulence factors to cause a variety of serious infections. P. aeruginosa (formerly Bacillus pyocyaneus) was originally isolated in pure culture by a French pharmacist named Gessard in 1882.1 The organism is ubiquitous in nature, has minimal growth requirements, is nutritionally versatile, and thrives in moist environments.2


Journal of the American Society for Mass Spectrometry | 2018

Top down tandem mass spectrometric analysis of a chemically modified rough-type lipopolysaccharide vaccine candidate

Benjamin L. Oyler; Mohd M. Khan; Donald F. Smith; Erin Harberts; David P. A. Kilgour; Robert K. Ernst; Alan S. Cross; David R. Goodlett

AbstractRecent advances in lipopolysaccharide (LPS) biology have led to its use in drug discovery pipelines, including vaccine and vaccine adjuvant discovery. Desirable characteristics for LPS vaccine candidates include both the ability to produce a specific antibody titer in patients and a minimal host inflammatory response directed by the innate immune system. However, in-depth chemical characterization of most LPS extracts has not been performed; hence, biological activities of these extracts are unpredictable. Additionally, the most widely adopted workflow for LPS structure elucidation includes nonspecific chemical decomposition steps before analyses, making structures inferred and not necessarily biologically relevant. In this work, several different mass spectrometry workflows that have not been previously explored were employed to show proof-of-principle for top down LPS primary structure elucidation, specifically for a rough-type mutant (J5) E. coli-derived LPS component of a vaccine candidate. First, ion mobility filtered precursor ions were subjected to collision induced dissociation (CID) to define differences in native J5 LPS v. chemically detoxified J5 LPS (dLPS). Next, ultra-high mass resolving power, accurate mass spectrometry was employed for unequivocal precursor and product ion empirical formulae generation. Finally, MS3 analyses in an ion trap instrument showed that previous knowledge about dissociation of LPS components can be used to reconstruct and sequence LPS in a top down fashion. A structural rationale is also explained for differential inflammatory dose-response curves, in vitro, when HEK-Blue hTLR4 cells were administered increasing concentrations of native J5 LPS v. dLPS, which will be useful in future drug discovery efforts.n Graphical Abstractᅟ


Journal of the American Society for Mass Spectrometry | 2018

Correction to: Top Down Tandem Mass Spectrometric Analysis of a Chemically Modified Rough-Type Lipopolysaccharide Vaccine Candidate

Benjamin L. Oyler; Mohd M. Khan; Donald F. Smith; Erin Harberts; David P. A. Kilgour; Robert K. Ernst; Alan S. Cross; David R. Goodlett

In the preceding article “Top Down Tandem Mass Spectrometric Analysis of a Chemically Modified Rough-Type Lipopolysaccharide Vaccine Candidate” by Oyler et al., an error in the J5 E. coli LPS chemical structure (Figs.xa02 and 4) was introduced and propagated into the final revision.


Annals of Internal Medicine | 1978

Septicemia and Chronic Hemodialysis

Alan S. Cross; Roy T. Steigbiegel

Excerpt To the editor: In their article, Septicemia in Patients on Chronic Hemodialysis (Ann Intern Med88:28-33, 1978), Dobkin, Miller, and Steigbigel take issue with our recommendation that acc...


The Journal of Infectious Diseases | 1989

Oral Ciprofloxacin and a Monoclonal Antibody to Lipopolysaccharide Protect Leukopenic Rats from Lethal Infection with Pseudomonas aeruginosa

Hugh Collins; Alan S. Cross; Arthur S. Dobek; Steven M. Opal; J. Bruce McClain; Jerald C. Sadoff


Vaccine | 2004

Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis

Alan S. Cross; Steven M. Opal; Pamela Cook; Joseph J. Drabick; Apurba K. Bhattacharjee


American Journal of Clinical Pathology | 1974

Outbreak of a nosocomial infection with a strain of Proteus rettgeri resistant to many antimicrobials.

Lawerence D. Edwards; Alan S. Cross; Stuart Levin; William Landau


Archive | 2005

Method of treating inflammation with inhibitors of sialyl transferases

Alan S. Cross; Nicholas M. Stamatos; Simeon E. Goldblum


Archive | 2004

Use of sialic acid, analogues of sialic acid, and antibodies to sialidases as anti-infectious agents and anti-inflammatory agents

Alan S. Cross; Nicholas M. Stamatos


American Journal of Clinical Pathology | 1983

A Hospital-wide Outbreak of Septicemia due to a Few Strains of Staphylococcus aureus

Alan S. Cross; Charles H. Zierdt; Brenda Roup; Rebecca Almazan; Judith C. Swan

Collaboration


Dive into the Alan S. Cross's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jeffrey D. Hasday

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge